Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

1.2K
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
1.2K
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

2.4K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.4K
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

926
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
926
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

353
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
353
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

263
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
263
Liver Regeneration01:24

Liver Regeneration

5.3K
The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
5.3K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Liver Fibrosis, But No Other Histologic Features, Is Associated With Long-term Outcomes Of Patients With Nonalcoholic Fatty Liver Disease.

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.

Paul Angulo1, David E Kleiner2, Sanne Dam-Larsen3

  • 1Division of Digestive Diseases and Nutrition, University of Kentucky Medical Center, Lexington, Kentucky.

Gastroenterology
|May 4, 2015

Related Experiment Videos

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

1.2K
Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.9K
Isolation of Regenerating Hepatocytes after Partial Hepatectomy in Mice
10:04

Isolation of Regenerating Hepatocytes after Partial Hepatectomy in Mice

Published on: December 2, 2022

6.0K

View abstract on PubMed

Summary
This summary is machine-generated.

Liver fibrosis stage is a key predictor of long-term outcomes in nonalcoholic fatty liver disease (NAFLD). Advanced fibrosis significantly increases mortality, liver transplantation, and liver-related events in NAFLD patients.

Area of Science:

  • Hepatology
  • Pathology
  • Clinical Research

Background:

  • Nonalcoholic fatty liver disease (NAFLD) diagnosis relies on liver biopsy for grading and staging.
  • Longitudinal data on the prognostic significance of NAFLD histologic features are crucial for patient management.

Purpose of the Study:

  • To investigate the long-term prognostic relevance of liver biopsy histologic features in patients with NAFLD.
  • To determine the association between fibrosis stage and other histologic findings with mortality, liver transplantation, and liver-related events.

Main Methods:

  • Retrospective analysis of 619 NAFLD patients diagnosed between 1975-2005.
  • Longitudinal follow-up with laboratory and biopsy analyses, with examinations every 3-12 months.
  • Statistical analysis using log-rank and Cox proportional-hazards regression to assess outcomes.
Keywords:
NASHPRELHIN StudyPredictionPrognosis

Related Experiment Videos

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

1.2K
Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.9K
Isolation of Regenerating Hepatocytes after Partial Hepatectomy in Mice
10:04

Isolation of Regenerating Hepatocytes after Partial Hepatectomy in Mice

Published on: December 2, 2022

6.0K

Main Results:

  • Fibrosis stage was significantly associated with increased risk of death or liver transplantation (Stage 1-4 HRs: 1.88-10.9).
  • Age, diabetes, and current smoking also predicted adverse outcomes, while statin use showed a protective effect.
  • Advanced fibrosis (Stage 3-4) strongly predicted liver-related events (HRs: 14.2-51.5).

Conclusions:

  • Liver fibrosis stage, independent of other steatohepatitis features, is a significant predictor of long-term mortality and adverse liver outcomes in NAFLD.
  • Histologic fibrosis assessment is critical for prognostication in NAFLD patients.
  • Patients with any degree of fibrosis demonstrated reduced survival compared to those without fibrosis.